PMID- 21267687
OWN - NLM
STAT- MEDLINE
DCOM- 20111220
LR  - 20211020
IS  - 1532-2807 (Electronic)
IS  - 1219-4956 (Linking)
VI  - 17
IP  - 3
DP  - 2011 Sep
TI  - The evaluation of CD99 immunoreactivity and EWS/FLI1 translocation by 
      fluorescence in situ hybridization in central PNETs and Ewing's sarcoma family of 
      tumors.
PG  - 619-25
LID - 10.1007/s12253-010-9358-3 [doi]
AB  - Ewing's sarcoma family of tumors (ESFTs) are indicated by malignant, small, round 
      and blue cell tumors of the bone and soft tissue. Gene rearrangements between EWS 
      gene on chromosome 22q12 and members of the ETS gene family are common in and 
      specific to ESFTs. Another defining characteristic of ESFTs is their membranous 
      expression of the CD99. In contrast, such translocations and immunoreactivity are 
      not found in central primitive neuroectodermal tumors (cPNETs). The aim of this 
      study was to investigate the detection of EWS/FLI1 translocations and CD99 
      immunoreactivity in order to evaluate their clinicopathological features and 
      their roles in the differential diagnosis of these tumors. In this study, we 
      investigated CD99 immunoreactivity using immunohistochemistry and Ewing's sarcoma 
      / Friend leukaemia virus integration 1 (EWS/FLI1) translocation using the 
      fluorescence in situ hybridization (FISH) method in 23 cases. CD99 expression was 
      detected in 10/11 (90%) ESFT cases and 2/7 cPNET cases. In 18 cases EWS/FLI1 
      translocation was examined using the FISH method. The EWS/FLI1 translocations 
      were detected in 7/8 (87.5%) ESFTs cases, whereas non of 8 cPNET cases were 
      detected with this translocation. One case could not be classified as either 
      central or peripheral, showed EWS/FLI1 translocation. There was a statistically 
      significant difference in CD99 expression (p = 0.0013) and EWS/FLI1 translocation 
      (p = 0,002) between cPNETs and ESFTs cases. In conclusion, CD99 expression and 
      EWS/FLI1 translocation are specific and sensitive markers in the diagnosis of 
      ESFTs. However, these were often not found in cases of cPNET. Therefore, in the 
      diagnosis of ESFTs, clinical, radiological, histopathological and 
      immunohistochemical parameters should always be evaluated together.
FAU - Vural, Cigdem
AU  - Vural C
AD  - Department of Pathology, Baskent University Faculty of Medicine, Ankara, Turkey. 
      dr.cvural@gmail.com
FAU - Uluoglu, Omer
AU  - Uluoglu O
FAU - Akyurek, Nalan
AU  - Akyurek N
FAU - Oguz, Aynur
AU  - Oguz A
FAU - Karadeniz, Ceyda
AU  - Karadeniz C
LA  - eng
PT  - Journal Article
DEP - 20110126
PL  - Switzerland
TA  - Pathol Oncol Res
JT  - Pathology oncology research : POR
JID - 9706087
RN  - 0 (12E7 Antigen)
RN  - 0 (Antigens, CD)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CD99 protein, human)
RN  - 0 (Cell Adhesion Molecules)
RN  - 0 (EWS-FLI fusion protein)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (Proto-Oncogene Protein c-fli-1)
RN  - 0 (RNA-Binding Protein EWS)
SB  - IM
MH  - 12E7 Antigen
MH  - Adolescent
MH  - Adult
MH  - Antigens, CD/*metabolism
MH  - Biomarkers, Tumor/genetics/metabolism
MH  - Bone Neoplasms/genetics/metabolism/pathology
MH  - Cell Adhesion Molecules/*metabolism
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Neuroectodermal Tumors, Primitive, Peripheral/*genetics/*metabolism/pathology
MH  - Oncogene Proteins, Fusion/*genetics
MH  - Prognosis
MH  - Proto-Oncogene Protein c-fli-1/*genetics
MH  - RNA-Binding Protein EWS/*genetics
MH  - Retrospective Studies
MH  - Sarcoma, Ewing/*genetics/*metabolism/pathology
MH  - *Translocation, Genetic
MH  - Young Adult
EDAT- 2011/01/27 06:00
MHDA- 2011/12/21 06:00
CRDT- 2011/01/27 06:00
PHST- 2010/05/05 00:00 [received]
PHST- 2010/12/29 00:00 [accepted]
PHST- 2011/01/27 06:00 [entrez]
PHST- 2011/01/27 06:00 [pubmed]
PHST- 2011/12/21 06:00 [medline]
AID - 10.1007/s12253-010-9358-3 [doi]
PST - ppublish
SO  - Pathol Oncol Res. 2011 Sep;17(3):619-25. doi: 10.1007/s12253-010-9358-3. Epub 
      2011 Jan 26.